-+ 0.00%
-+ 0.00%
-+ 0.00%

REVOLUTION MEDICINES ANNOUNCES FIRST PATIENT RANDOMIZED IN THE RASOLUTE 304 CLINICAL TRIAL OF DARAXONRASIB IN RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA FOLLOWING ADJUVANT CHEMOTHERAPY

路透·12/18/2025 13:00:05

登录查看新闻详情